ENGLEWOOD CLIFFS, NJ – May 9,  2023 – Silo Pharma, Inc.  (NASDAQ: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced that the U.S. Patent and Trademark Office (USPTO) has issued U.S. Patent 11,622,948 titled “Biomarkers for Efficacy of Prophylactic Treatments Against Stress-Induced Affective Disorders.” The new patent claims cover the use of biomarkers in determining the efficacy of the Company’s portfolio drug SPC-15, a targeted prophylactic treatment utilizing ketamine compositions, as a method of treatment for a stress-induced affective disorder or stress-induced psychopathology.

“This patent is an important addition to our intellectual property, further protecting the key technology behind SPC-15 in which metabolomic biomarkers predict the response to pharmacological treatments and measure efficacy,” said Eric Weisblum, Chief Executive Officer of Silo Pharma. “Based on our latest research with Columbia University on SPC-15, this IP expands the claims of the original patent.”

Silo Pharma owns an option to license certain assets currently undergoing studies at Columbia University for stress-induced affective disorders and Alzheimer’s disease.

About Silo Pharma 

Silo Pharma. Inc. is a development-stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research for people suffering from indications such as PTSD, Alzheimer’s disease, and other rare neurological disorders. Silo’s mission is to identify assets to license and fund the research which we believe will be transformative to the well-being of patients and the healthcare industry. For more information visit www.silopharma.com

Forward-Looking Statements 

All statements other than statements of historical fact in this announcement are forward-looking statements that involve known and unknown risks and uncertainties and are based on current expectations and projections about future events and financial trends that the Company believes may affect its financial condition, results of operations, business strategy, and financial needs. Investors can identify these forward-looking statements by words or phrases such as “may,” “will,” “expect,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “potential,” “continue,” “is/are likely to” or other similar expressions. The Company under takes no obligation to update forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company’s filings with the SEC.

Contact 

800-705-0120

investors@silopharma.com

SOURCE:  Silo Pharma, Inc.

The post Silo Pharma’s SPC-15 Awarded U.S. Patent to Protect Ongoing R&D of Therapeutic for Stress-Induced Affective Disorder and Alzheimer’s Disease appeared first on Financial News Media.